IN8bio shares surge 12.94% intraday after presenting promising DeltEx glioblastoma trial results showing improved survival rates.

IN8bio surged 12.94% intraday after announcing positive clinical trial results for its gamma-delta T cell therapy, DeltEx™, in glioblastoma patients, demonstrating improved survival rates compared to standard care. The data, presented during the trading session, highlighted the therapy’s potential as a breakthrough treatment, boosting investor confidence in the company’s pipeline. A separate corporate presentation disclosed a $200 million mixed shelf offering and a narrowed Q3 net loss, but the clinical trial news was the primary catalyst for the sharp intraday rally.